Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: Patterns of resource utilization and cost for postmenopausal women with hormone-receptor–positive, human epidermal growth factor receptor-2–negative advanced breast cancer in Europe

Fig. 2

Direct overall costs by patient cohort. The costs in cohort A were significantly lower than the costs in cohort C (p < 0.001, Mann-Whitney U test). Average treatment durations by type and line of therapy in each cohort are shown in parentheses. Abbreviations: HT, hormone therapy; Tx, treatment; wk, week(s)

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us